Navigation Links
Express Scripts to Present at Investor Conferences in November
Date:10/25/2010

ST. LOUIS, Oct. 25 /PRNewswire/ -- Express Scripts, Inc. (Nasdaq: ESRX) announced that it will present at the following investor conferences in November:Oppenheimer 21st Annual Healthcare Conference on Wednesday, November 3, 2010 at 1:35 p.m. eastern.Credit Suisse 2010 Healthcare Conference on Wednesday, November 10, 2010 at 8:30 a.m. mountain (10:30 a.m. eastern).Lazard Capital Markets' 7th Annual Healthcare Conference on Tuesday, November 16, 2010 at 9:55 a.m. eastern. These presentations will also be broadcast via the Internet and can be accessed on the investor relations section of Express Scripts web site at http://www.express-scripts.com.  RealPlayer or Windows Media Player is needed to listen to the Webcasts and free downloads of these players are available at the Webcast site. The Webcasts will be archived and available for replay for 14 days.

Express Scripts, Inc., one of the largest pharmacy benefit management companies in North America, is leading the way toward creating better health and value for patients through Consumerology®, the advanced application of the behavioral sciences to healthcare. This approach is helping millions of members realize greater healthcare outcomes and lowering cost by assisting in influencing their behavior. Headquartered in St. Louis, Express Scripts provides integrated PBM services including network-pharmacy claims processing, home delivery services, specialty benefit management, benefit-design consultation, drug-utilization review, formulary management, and medical and drug data analysis services. The company also distributes a full range of biopharmaceutical products and provides extensive cost-management and patient-care services. More information can be found at http://www.express-scripts.com/ and

SOURCE Express Scripts, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ALS TDI Completes Gene Expression Profile of Lou Gehrigs Disease in Mice
2. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
3. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
4. TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
5. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
6. Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
7. Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients
8. International Medical Corps Matched with Top 25 American Express Members Project, Saving the Lives of Malnourished Children
9. TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program
10. SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS(R) Express2(TM) Stents and Bypass Surgery
11. Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... -- Cardica, Inc. (Nasdaq: CRDC ) today announced that it ... June 30, 2015, on Thursday, August 6, 2015, after the ... 4:30 p.m. Eastern Time to discuss the financial results and ... Conference Call Details To access the live conference call on ... please dial 877-703-6106 from the United States ...
(Date:7/27/2015)... IRVINE, Calif. , July 27, 2015 ... ELOS ) , a global market leader in ... has received Korean Ministry of Food and Drug Safety ... this regulatory clearance, the Company can fulfill PicoWay orders ... activity in Korea anticipated later in the third quarter ...
(Date:7/27/2015)... YORK , July 27, 2015  Relmada ... novel therapies for the treatment of chronic pain, ... Trial Application (CTA) with Heath Canada ... study with d-Methadone (dextromethadone, REL-1017), its novel, N-methyl-D-aspartate ... of neuropathic pain. "We are very ...
Breaking Medicine Technology:Cardica To Announce Fiscal 2015 Fourth Quarter Financial Results On Thursday, August 6, 2015 2Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 2Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 3Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 4Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone 2Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone 3
... NEW YORK, June 3 Delcath Systems, Inc.,(Nasdaq: ... Center of,Bethlehem, PA, part of St. Luke,s Hospital & ... trial for the treatment of,inoperable metastatic melanoma in the ... the isolated, high dose,delivery of the anti-cancer agent melphalan. ...
... Data Presented at ASCO Show 26% Partial Response, 63% Clinical Benefit ... ... Calif., June 3 Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today ... antitumor activity in a Phase 2,trial when administered in combination with ...
Cached Medicine Technology:Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center 2Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center 3Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 2Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 3Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 4Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 5Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 6
(Date:7/28/2015)... ... July 28, 2015 , ... PeopleKeys today announced that their ... the EY Entrepreneur of the Year award. The award recognizes the important strides ... the innovative work they have done in incorporating new technology, processes, and procedures ...
(Date:7/28/2015)... ... ... Maryland Brain & Spine has adopted a new name – Maryland Brain, Spine ... techniques, and additional state-of-the art online resources for patients. MBSP is ... and spine conditions. , “Adding the word ‘pain’ may not seem like a ...
(Date:7/28/2015)... ... July 28, 2015 , ... One of the most common ... is plantar fasciitis . Zensah, the Miami-based compression brand, offers a product ... athletic trainer, the Zensah Ankle Support’s primary benefits include helping support the ankle, ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... to offer online RN to BSN cohorts for Geisinger Health System ... partnership provides GHS diploma and associate degree prepared nurses with access to American ...
(Date:7/28/2015)... ... July 28, 2015 , ... Carol McFarland, ... with discussion and demonstration of specific rehabilitation exercises and treatment protocols in the ... surgical process with an extensive interview conducted by Carol with a board certified ...
Breaking Medicine News(10 mins):Health News:Receiving Recognition for Compassionate Care and Innovative Processes: Celtic Healthcare CEO Arnie Burchianti Wins Regional EY Entrepreneur of the Year Award 2Health News:Receiving Recognition for Compassionate Care and Innovative Processes: Celtic Healthcare CEO Arnie Burchianti Wins Regional EY Entrepreneur of the Year Award 3Health News:Maryland Brain & Spine Announces New Specialty, New Name 2Health News:Maryland Brain & Spine Announces New Specialty, New Name 3Health News:Maryland Brain & Spine Announces New Specialty, New Name 4Health News:Zensah Releases Compression Sleeve To Relieve Ankle Pain and Plantar Fasciitis 2Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 2Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 3Health News:American Sentinel University Selected to Provide Online RN to BSN Cohorts to Geisinger Health System 4Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 2Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 3Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 4Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 5Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 6
... Still Has No System to Monitor MRSA in ... WASHINGTON, Dec. 3 A new study published ... Emerging Infectious,Diseases links a new strain of methicillin-resistant ... more than 20 percent of all human MRSA,infections ...
... LipoScience, Inc. is pleased to,announce the election of ... Mr. Landon has over 30 years of broad, multi-functional ... management, Mr. Landon,was Vice President & General Manager of ... for all of DuPont,s Medical,Products businesses, with total sales ...
... Neuro Kinetics, Inc., (http://www.neuro-kinetics.com ), manufacturers ... for balance, vestibular and neurological disorder,tests, ... has been appointed clinical director,audiology., ... testing, coordination of multi-,site research projects, ...
... Oncology (ESMO) is calling on European politicians to voice their ... receive the best possible treatment. , At a meeting ... States met in Brussels to consider the status of medical ... Such recognition is an essential step in providing optimal treatment ...
... with stimulants, antidepressants and other psychiatric drugs is ... lack of clinical practice guidelines. In a first ... professionals from the Bradley Hasbro Childrens Research Center ... specific disorders to help clinicians who are considering ...
... beat out college students in tests involving digits 1 through ... -- It may be a case of monkey see, monkey ... human adults at remembering numbers. , A team of Japanese ... had learned how to identify the numbers 1 through 9 ...
Cached Medicine News:Health News:New Study Links Animal Agriculture to More Than 20% of MRSA Infections in the Netherlands 2Health News:Neuro Kinetics Appoints Dr. Terri Ives Clinical Director, Audiology 2Health News:Cancer patients to be treated by qualified professionals 2Health News:Child mental health experts issue psychiatric medication treatment guidelines for preschoolers 2Health News:Child mental health experts issue psychiatric medication treatment guidelines for preschoolers 3Health News:Chimps Top Humans in Number Recall 2
Silicone Elastomer-Coated Latex Foley Catheters 2-Way...
Silicone Foley Catheters 3-Way...
Midstream Catch Kits...
... The BladderScan® BVI 6300 Bladder Monitor ... prescribed by the healthcare provider to ... on an ongoing basis. It is ... accurate results, so the patient can ...
Medicine Products: